MOUNJARO (TIRZEPATIDE) Posted or Updated on 30 Jun 2025

MOUNJARO (TIRZEPATIDE) FOR OBESITY MANAGEMENT

The local Integrated Care board (ICB) are responsible for ensuring provision of Mounjaro for weight loss in Primary care from 23^rd June 2025.

Like many areas, they are still finalising arrangements to gradually roll this out, focusing on the most at risk patients first.

Primary care does not mean “your GP” – primary care is all NHS health service provided in the community and includes pharmacies, opticians and commissioned local community clinics.

We have been told strictly that GPs MUST NOT prescribe Mounjaro. By the Autumn, the ICB will have local primary care centres providing weight management clinics to prescribe for:

·         BMI > 40 (or 37.5 for Asian, Chinese, middle eastern and Black ethnic backgrounds)

·         AND 4 or more of the following conditions:

·         Type 2 diabetes

·         Hypertension (formal diagnosis of high blood pressure)

·         Established cardiovascular disease (heart disease)

·         Obstructive sleep apnoea

·         Dyslipidaemia ( abnormal cholesterol / blood fats)

We hope to have a further update in the Autumn regarding referrals into this clinic so please check back on the website for details